Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | RAB9A, member RAS oncogene family | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ras-related protein Rab-5B | RAB9A, member RAS oncogene family | 201 aa | 165 aa | 30.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | musashi | 0.0033 | 1 | 1 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.1333 | 0.1333 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 1 | 0.5 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.9658 | 0.9658 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 1 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 1 | 1 |
Echinococcus multilocularis | lamin | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 1 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0342 | 0.0342 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0033 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1651 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 3.9811 um | PUBCHEM_BIOASSAY: qHTS Assay for Rab9 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 17.7828 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 30.1313 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2312, AID2537, AID2702] | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.